CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 1 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $120,142 | -27.7% | 5,503,498 | +5.3% | 0.02% | -21.7% |
| Q2 2023 | $166,097 | +41.9% | 5,224,800 | +8.9% | 0.02% | +27.8% |
| Q1 2023 | $117,066 | -22.7% | 4,799,707 | -0.1% | 0.02% | -25.0% |
| Q4 2022 | $151,537 | -99.9% | 4,804,594 | +0.7% | 0.02% | +9.1% |
| Q3 2022 | $134,775,000 | -19.0% | 4,769,074 | -24.3% | 0.02% | +4.8% |
| Q2 2022 | $166,464,000 | -26.6% | 6,295,908 | -2.8% | 0.02% | -8.7% |
| Q1 2022 | $226,795,000 | +16.6% | 6,478,010 | +8.0% | 0.02% | +27.8% |
| Q4 2021 | $194,550,000 | +12.9% | 6,000,922 | +2.7% | 0.02% | +12.5% |
| Q3 2021 | $172,302,000 | +102.1% | 5,840,731 | +75.5% | 0.02% | +100.0% |
| Q2 2021 | $85,248,000 | +82.6% | 3,327,411 | -2.1% | 0.01% | +60.0% |
| Q1 2021 | $46,680,000 | -13.6% | 3,399,888 | +0.2% | 0.01% | -16.7% |
| Q4 2020 | $54,003,000 | – | 3,392,133 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,912,345 | 41.46% |
| Perceptive Advisors | 6,511,727 | $205,379,869 | 5.77% |
| Finepoint Capital LP | 517,287 | $16,315 | 5.28% |
| Artal Group S.A. | 1,900,000 | $59,926 | 3.34% |
| Affinity Asset Advisors, LLC | 215,000 | $6,781,100 | 2.66% |
| Rock Springs Capital Management LP | 2,506,464 | $79,053,875 | 1.90% |
| Hood River Capital Management LLC | 923,638 | $29,131,543 | 1.06% |
| Logos Global Management LP | 260,000 | $8,200,400 | 0.96% |
| Frazier Life Sciences Management, L.P. | 393,000 | $12,395,220 | 0.77% |
| FEDERATED HERMES, INC. | 2,867,451 | $90,439,405 | 0.25% |